Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation
NCT ID: NCT02083809
Last Updated: 2020-11-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
166 participants
INTERVENTIONAL
2014-10-31
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
500ml saline or lactated ringer without oxytocin added
Intravenous Fluids and Electrolytes
500 ml of inert IV fluid
Treatment group
Intravenous oxytocin mixed with saline or lactated ringer
intravenous oxytocin
30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous oxytocin
30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
Intravenous Fluids and Electrolytes
500 ml of inert IV fluid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intrauterine pregnancy at 18- to 24-weeks gestation
* Gestational-age to be confirmed by ultrasound
* Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
* Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures
Exclusion Criteria
* Patients requiring preoperative misoprostol
14 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Society of Family Planning
OTHER
University of Washington
OTHER
University of Hawaii
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bliss Kaneshiro
Professor of Obstetrics & Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Hawaii
Honolulu, Hawaii, United States
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Whitehouse K, Tschann M, Soon R, Davis J, Micks E, Salcedo J, Savala M, Kaneshiro B. Effects of Prophylactic Oxytocin on Bleeding Outcomes in Women Undergoing Dilation and Evacuation: A Randomized Controlled Trial. Obstet Gynecol. 2019 Mar;133(3):484-491. doi: 10.1097/AOG.0000000000003104.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OxyDE
Identifier Type: -
Identifier Source: org_study_id